Combined formulations containing a liraglutide nanoformulation and an SGLT-2 inhibitor have been shown to significantly improve blood lipid profiles in patients with type 2 diabetes
The journey from the discovery of the GLP-1 hormone to the treatment of diabetes and then obesity has been a long and tortuous one, spanning more than four decades and involving hundreds of researchers from academia and the pharmaceutical industry
In particular, cardiolipin, a novel phospholipid synthesized in the mitochondria, may serve to trap deuterium that enters the intermembrane space before it reaches the ATPase pumps
FARXIGA is not recommended for use to improve glycemic control in patients with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m 2
It helps motivate me and keep me on track
Among individuals with diabetes, 43% report ever taking these medications, while 22% of those told they are overweight or obese have used them ^19